Next Article in Journal
Ultra-Short Cyclized β-Boomerang Peptides: Structures, Interactions with Lipopolysaccharide, Antibiotic Potentiator and Wound Healing
Next Article in Special Issue
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
Previous Article in Journal
Macrophages Release Extracellular Vesicles of Different Properties and Composition Following Exposure to Nanoparticles
Previous Article in Special Issue
Regulation of Cyclooxygenase-2 Expression in Human T Cells by Glucocorticoid Receptor-Mediated Transrepression of Nuclear Factor of Activated T Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

MicroRNAs in T Cell-Immunotherapy

by
Sara G. Dosil
1,2,3,
Ana Rodríguez-Galán
1,2,3,
Francisco Sánchez-Madrid
1,2,3,4 and
Lola Fernández-Messina
1,2,3,4,5,*
1
Immunology Service, Hospital Universitario de la Princesa, Instituto Investigación Sanitaria Princesa, 28006 Madrid, Spain
2
Intercellular Communication in the Inflammatory Response, Vascular Pathophysiology Area, National Center for Cardiovascular Research (CNIC), 28029 Madrid, Spain
3
Universidad Autónoma de Madrid, 28049 Madrid, Spain
4
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
5
Department of Cell Biology, Faculty of Biological Sciences, Universidad Complutense de Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(1), 250; https://doi.org/10.3390/ijms24010250
Submission received: 11 November 2022 / Revised: 6 December 2022 / Accepted: 15 December 2022 / Published: 23 December 2022
(This article belongs to the Special Issue State-of-the-Art Molecular Immunology in Spain)

Abstract

MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies.
Keywords: microRNAs (miRNAs); antagomiRNAs (antagomiRs); immunotherapy; T cell immunotherapy; nanoparticles (NPs); nanomedicine; miRNA delivery microRNAs (miRNAs); antagomiRNAs (antagomiRs); immunotherapy; T cell immunotherapy; nanoparticles (NPs); nanomedicine; miRNA delivery

Share and Cite

MDPI and ACS Style

Dosil, S.G.; Rodríguez-Galán, A.; Sánchez-Madrid, F.; Fernández-Messina, L. MicroRNAs in T Cell-Immunotherapy. Int. J. Mol. Sci. 2023, 24, 250. https://doi.org/10.3390/ijms24010250

AMA Style

Dosil SG, Rodríguez-Galán A, Sánchez-Madrid F, Fernández-Messina L. MicroRNAs in T Cell-Immunotherapy. International Journal of Molecular Sciences. 2023; 24(1):250. https://doi.org/10.3390/ijms24010250

Chicago/Turabian Style

Dosil, Sara G., Ana Rodríguez-Galán, Francisco Sánchez-Madrid, and Lola Fernández-Messina. 2023. "MicroRNAs in T Cell-Immunotherapy" International Journal of Molecular Sciences 24, no. 1: 250. https://doi.org/10.3390/ijms24010250

APA Style

Dosil, S. G., Rodríguez-Galán, A., Sánchez-Madrid, F., & Fernández-Messina, L. (2023). MicroRNAs in T Cell-Immunotherapy. International Journal of Molecular Sciences, 24(1), 250. https://doi.org/10.3390/ijms24010250

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop